Organon & Co. (NYSE:OGN) Trading Down 6.3% – Time to Sell?

Organon & Co. (NYSE:OGN)’s stock price traded down 6.3% during trading on Wednesday . The company traded as low as $7.65 and last traded at $7.63. 2,430,424 shares were traded during mid-day trading, a decline of 58% from the average session volume of 5,848,301 shares. The stock had previously closed at $8.14.

Analyst Ratings Changes

Several equities analysts recently issued reports on the company. Zacks Research cut Organon & Co. from a “hold” rating to a “strong sell” rating in a research report on Thursday, January 29th. JPMorgan Chase & Co. dropped their target price on Organon & Co. from $14.00 to $12.00 and set an “underweight” rating on the stock in a report on Tuesday, November 11th. Morgan Stanley decreased their price target on Organon & Co. from $10.00 to $9.00 and set an “equal weight” rating for the company in a report on Tuesday, November 11th. Wall Street Zen cut shares of Organon & Co. from a “buy” rating to a “hold” rating in a research note on Saturday, January 31st. Finally, Barclays upped their price objective on shares of Organon & Co. from $7.50 to $8.00 and gave the stock an “underweight” rating in a research report on Tuesday. One investment analyst has rated the stock with a Strong Buy rating, one has issued a Hold rating and five have issued a Sell rating to the company. Based on data from MarketBeat, the company presently has an average rating of “Reduce” and a consensus price target of $8.50.

Organon & Co. Trading Down 7.8%

The stock has a market cap of $1.95 billion, a PE ratio of 10.57, a P/E/G ratio of 0.72 and a beta of 0.58. The business’s fifty day moving average is $7.97 and its 200 day moving average is $8.50. The company has a quick ratio of 1.20, a current ratio of 1.75 and a debt-to-equity ratio of 9.69.

Organon & Co. (NYSE:OGN) last issued its earnings results on Thursday, February 12th. The company reported $0.63 earnings per share (EPS) for the quarter, missing analysts’ consensus estimates of $0.73 by ($0.10). The company had revenue of $1.51 billion during the quarter, compared to analysts’ expectations of $1.52 billion. Organon & Co. had a net margin of 3.01% and a return on equity of 123.06%. The company’s quarterly revenue was down 5.3% on a year-over-year basis. During the same period last year, the business posted $0.90 earnings per share. As a group, analysts predict that Organon & Co. will post 3.68 earnings per share for the current year.

Organon & Co. Dividend Announcement

The company also recently disclosed a quarterly dividend, which will be paid on Thursday, March 12th. Investors of record on Monday, February 23rd will be issued a dividend of $0.02 per share. The ex-dividend date of this dividend is Monday, February 23rd. This represents a $0.08 annualized dividend and a yield of 1.1%. Organon & Co.’s payout ratio is currently 11.27%.

Institutional Inflows and Outflows

Several hedge funds and other institutional investors have recently made changes to their positions in OGN. Hantz Financial Services Inc. grew its stake in Organon & Co. by 293.8% in the 2nd quarter. Hantz Financial Services Inc. now owns 2,674 shares of the company’s stock valued at $26,000 after acquiring an additional 1,995 shares during the last quarter. Foster Dykema Cabot & Partners LLC acquired a new stake in shares of Organon & Co. in the third quarter valued at approximately $29,000. Farther Finance Advisors LLC increased its stake in shares of Organon & Co. by 87.8% during the 4th quarter. Farther Finance Advisors LLC now owns 4,349 shares of the company’s stock worth $31,000 after purchasing an additional 2,033 shares in the last quarter. SouthState Corp increased its stake in shares of Organon & Co. by 1,857.0% during the 2nd quarter. SouthState Corp now owns 3,914 shares of the company’s stock worth $38,000 after purchasing an additional 3,714 shares in the last quarter. Finally, Rothschild Investment LLC raised its position in shares of Organon & Co. by 73.1% during the 3rd quarter. Rothschild Investment LLC now owns 3,899 shares of the company’s stock worth $42,000 after purchasing an additional 1,646 shares during the last quarter. Institutional investors and hedge funds own 77.43% of the company’s stock.

Organon & Co. Company Profile

Organon & Co is a global healthcare company that was established as an independent, publicly traded entity following its spin-off from Merck & Co in June 2021. Headquartered in Jersey City, New Jersey, Organon focuses on delivering therapeutic solutions across women’s health, biosimilars, and established brands. The company’s creation reflected a strategic effort to concentrate on specialty pharmaceuticals and legacy products with proven patient impact.

In women’s health, Organon provides a broad portfolio of products addressing reproductive and gynecological conditions, including fertility treatments, contraception, and hormone replacement therapies.